A treatment for patients living with advanced non-small cell lung cancer (NSCLC) who failed two or more standard-of-care (SOC) options could extend overall survival (OS) to 16.9 months according to ...

Regeneron has announced that the European Commission (EC) has approved Libtayo (cemiplimab ... Trial groups (ENGOT), and NRG Oncology-Japan. Patients were of a median age of 51 years old ...

It was a busy week for the biotech sector as the fourth-quarter earnings season kicked in. While Regeneron REGN gained following the announcement, Amgen AMGN was in the red. Meanwhile, other pipeline ...

and Regeneron’s Libtayo (cemiplimab), if approved. Checkpoint has said it may position cosibelimab as a low-cost alternative in the category, backed up by clinical results that suggest its ...

The therapeutic candidate is used in combination with REGN-4018 and LIBTAYO. Regeneron Pharmaceuticals (Regeneron ... It operates in the US, the Netherlands, Bermuda, Ireland, Spain, India, Japan and ...

Cemiplimab (Libtayo) is an anti-neoplastic agent ... It operates in the US, the Netherlands, Bermuda, Ireland, Spain, India, Japan and the UK. Regeneron is headquartered in Tarrytown, New York, the US ...

Regeneron's Q4 earnings report shows revenue growth, stable EYLEA sales, dividend announcement, and impressive growth for ...

Moments after Regeneron CEO Len Schleifer scolded analysts for asking too many questions about the disappointing sales of eye ...

Immuneering plans to evaluate IMM-1-104 in combination with Libtayo in patients with advanced non-small cell lung cancer in its ongoing Phase 2a trial – - Data presented at AACR 2023 supports ...

Immuneering Corporation (IMRX), a clinical-stage oncology company, Thursday said it has signed a clinical supply agreement with ...

Immuneering (IMRX) announced a clinical supply agreement with Regeneron Pharmaceuticals (REGN) for its anti-PD-1 therapy, Libtayo. The supply ...

Regeneron's 2025 outlook includes defensive capital allocation, competitive pressure on Eylea, et cetera. Click here to read ...